Glidimin 2 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 2mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, contributing to better glycemic control. This combination offers complementary mechanisms of action, making it effective for patients inadequately controlled on monotherapy. Glidimin 2 Tablet PR is administered orally, typically once or twice daily with meals to minimize gastrointestinal side effects associated with Metformin. It is essential to monitor blood glucose levels regularly and adjust dosage based on therapeutic response and tolerability. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to hypoxia, as these may increase the risk of lactic acidosis, a rare but serious adverse effect of Metformin. Hypoglycemia risk is heightened due to Glimepiride’s insulinotropic effect, necessitating patient education on recognizing and managing low blood sugar episodes. Glidimin 2 Tablet PR should be used as part of a comprehensive diabetes management plan, including diet, exercise, and regular medical supervision.